Search

1510 Result(s)
Sort by

The power of patient advocacy in cancer care

The power of patient advocacy in cancer care

Larry, a retired US Navy veteran, and Jeff, UICC President, have more in common than a cancer diagnosis: they share a passion for patient empowerment.
CHMP_opinion_Nintedanib_SSc-ILD

CHMP_opinion_Nintedanib_SSc-ILD

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
commitments to sustainable development

commitments to sustainable development

On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
“My ultimate goal is to cure cancer”

“My ultimate goal is to cure cancer”

Norbert Kraut, our Global Head of Cancer Research, shares how we are advancing science to bring new treatment options for people living with cancer.
Clinical-phase2-trials-NASH-and-obesity

Clinical-phase2-trials-NASH-and-obesity

Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
collaboration-LIBD

collaboration-LIBD

Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
Retinal Health Research

Retinal Health Research

Our research is targeting key mechanisms in the pathogenesis of retinal diseases – vascular dysfunction, neuronal dysfunction and neuronal inflammation.
university-of-medical-excellence-harvard

university-of-medical-excellence-harvard

A program designed by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs